Correlation between anti-dsDNA, complement components C3, C4 and Systemeic Lupus Erythematosus disease activity index

Öz

Background: To find out the correlation between anti-ds DNA, complement components C3, C34 and disease activity in SLE. Material and Methods: This cross-sectional study was undertaken over a period of 6 months from January 2016 to June 2016 at a Tertiary Care Centre in South India.  Blood samples were collected from 100 patients with active lupus, 100 patients with inactive disease and 100 healthy controls. Serum samples from all the 300 samples were tested for anti- dsDNA by ELISA and C3, C4 by Radial Immunodiffusion. Results: High titre anti-dsDNA was detected in 48 out of the 100 patients with active disease. Mean SLE disease activity index (SLEDAI) of patients with high titre anti-dsDNA was 23.08337 ± 3.80276 (P<0.001) Mean SLEDAI of patients with very low C3 and C4 was 21.4314 ± 4.88776 (P<0.001) and  21.1250 ± 4.82882 (P<0.001).  Conclusion: Anti-dsDNA, C3, C4 levels can be adopted as markers of disease activity in SLE. Anti-dsDNA by ELISA is a simple and cost effective method. Radial immunodiffusion can be done for C3 and C4 assay where nephelometer is not available as the procedure is simple.

Anahtar Kelimeler

• Systemic Lupus Erythematosus
• anti-ds DNA antibody
• ELISA
• C3
• C4
• radial immuno diffusion

Kaynakça

1. 1. Hohan C, Datta SK. Lupus key pathogenic mechanisms and contributing factors. Clin Immunol Immunopathol. 1996; 77:209-220.
2. 2. Daniel Wallace, Bevra Hahn. Dubois Lupus Erythematosus and Related Syndromes 8th edition, Elsevier, Saunders, 2012; Chapter 43:p526.
3. 3. Solomon DH, Kavanough AJ, Schur PH, and American College of Rheumatology Ad Hoc Committee on immunologic Testing Guidelines: Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing: Arthritis Rheum 2002; 47:434-444.
4. 4. Daniel Wallace, Bevra Hahn. Dubois Lupus Erythematosus and Related Syndromes 8th edition, Elsevier, Saunders, 2012; Chapter 20:p275.
5. 5. Isenberg D. Smenk R. Clinical laboratory assays for measuring anti-dsDNA antibodies. Where are we now? Lupus. 2001;11:797-800.
6. 6. Hermann M.VollR.KaldenVR.Etiopathogenesis of systemic lupus erythematosus. Immunol Today. 2000;21:424-426.
7. 7. Sturfelt G.Truedsson complement and its breakdown products in SLE. Rheumatol. 2005;44:1227-1232.
8. 8. Daniel Wallace, Bevra Hahn. Dubois Lupus Erythematosus and Related Syndromes 8th edition, Elsevier, Saunders, 2012; Chapter 43 P:527.

9. 9. RadiceA. Sinico RA. A new oligonucleotide-based ELISA for the detection of anti-double stranded DNA antibodies-Autoimmunity 2006;39:113-119.
10. 10. Bruns A. Blass S. Hausdorf G. Burmester GR. HiepeF. Bruns A. BlassS. Hausdorf G.Burmester GR. Hiepe F. Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 2000;43:2307-2315.
11. 11. Daniel Wallace, Bevra Hahn. Dubois Lupus Erythematosus and Related Syndromes 8th edition, Elsevier, Saunders, 2012; Chapter 43 P:427.
12. 12. Bootsma H. Spronk P. Derksen R, et al. Prevention of relapses in systemic lupus erythematosus. Lancet. 1995; 345(8965):1595-1599.
13. 13. Tseng CE, Buyon JP, Kim M. The effect of moderate dose cortico steroids in preventing severe lupus erythematosus findings of a prospective, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2006;54(11)3623:36-32.
14. 14. Daniel Wallace, Bevra Hahn. Dubois Lupus Erythematosus and Related Syndromes 8th edition, Elsevier Saunders, 2012; Chapter 43:275.
15. 15. Eilat DT. The measurement of anti-DNA creativity in the sera of patients with SLE Theoretical and practical considerations. Autoimmunity. 1989;3:299-6.
16. 16. Isenberg DA, Dueney-C, Williams E, et al. Measurement of anti-DNA antibodies; a reappraisal using five different methods. Ann Rheum Dis. 1987;46:448-56.
17. 17. Daniel Wallace, Bevra Hahn. Dubois Lupus Erythematosus and Related Syndromes 8th edition, Elsevier, Saunders, 2012; Chapter 20:p325.
18. 18. Ng KP, Manson JJ, Rahman A. Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Care Res. 2006;55:900-904.
19. 19. Daniel Wallace, Bevra Hahn. Dubois Lupus Erythematosus and Related Syndromes 8th edition, Elsevier, Saunders, 2012; Chapter 43:p526
20. 20. Schur PH, Sandson J. Immunological factors and clinical activity in systemic lupus erythematosus. N Engl J Med. 1968; 278:533-538.
21. 21. Vaughan JH, Bayles TB, Favour CB. The response of serum gamma globulin level and complement titer to adrenocorticotrophic harmone (ACTH) therapy in lupus erythematosus disseminates. J Lab Clin Med. 1951;37:698-702.
22. 22. Ho A, Barr SG, Magder LS. A decrease in complement is associated with increased renal and hematological activity in patients with systemic erythematosus. Arthritis Rheum. 2001; 44:2350-2357.
23. 23. Lloyd W, Schur PH. Immune complexes, complement and anti-DNA in exacerbations of systemic lupus erythematosus (SLE), Medicine. 1981;60:208-217.
24. 24. Valentijn RM, van Overhagen H, Hazevoet HM, Hermans J, Cats A, et al. The value of complement and immune complex determinations in monitoring disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 1985;28:904-913.
25. 25. Cameron JS, Lessof MH, Ogg CS, Williams BD, Williams DG. Disease activity in the Nephritis of systemic lupus erythematosus in relation to serum complement concentrations, DNA-binding capacity, and precipitating anti-DNA antibody. Clin Exp Immunol. 1976;25(3):418-427.
26. 26. Swaak J, Groenwold J, Broaxveld W. Predictive value of complement profiles and anti-dsDNA in systemic erythematosus. Ann Rhuem Dis. 1986;45:359-366.
27. 27. Reichlin M. ANA negative systemic lupus erythematosus sera revised serologically. Lupus. 2000;9(2):116-119.